Contact
searchSearch
HMP Global

Biosimilars Topic Center

News
Balancing Clinical Outcomes and Cost: The Value of Biosimilars in Retinal Disease Management
09/26/2025
Juliet Gallagher
A recent study examining the impact of retinal diseases highlights their significant clinical, social, and economic burden.
A recent study examining the impact of retinal diseases highlights their significant clinical, social, and economic burden.
A recent study examining the...
09/26/2025
First Report Managed Care
News
Policy Impact: FDA’s Interchangeability Designation Expands Biosimilar Access
09/25/2025
Juliet Gallagher
Insulin glargine, marketed as Semglee and its biosimilar insulin glargine-yfgn, was granted interchangeable status, allowing pharmacists to substitute it for the branded originator without requiring prescriber intervention. A new economic...
Insulin glargine, marketed as Semglee and its biosimilar insulin glargine-yfgn, was granted interchangeable status, allowing pharmacists to substitute it for the branded originator without requiring prescriber intervention. A new economic...
Insulin glargine, marketed as...
09/25/2025
First Report Managed Care
News
How Timing Shapes Biosimilar Success: Insights from US Market Data
09/24/2025
Juliet Gallagher
A recent study published in Value in Health sheds light on the competitive dynamics of biosimilar drugs in the US, specifically examining whether first-mover advantages resemble those seen in generic drug markets.
A recent study published in Value in Health sheds light on the competitive dynamics of biosimilar drugs in the US, specifically examining whether first-mover advantages resemble those seen in generic drug markets.
A recent study published in...
09/24/2025
First Report Managed Care
News
Biosimilars Match Humira in Structure, Show Greater Stability Under Real-World Stress
09/22/2025
Juliet Gallagher
A new analytical study underscores how advanced nuclear magnetic resonance (NMR) spectroscopy can sharpen head-to-head comparisons between Humira (adalimumab) and its biosimilars—particularly when products are challenged under real-world...
A new analytical study underscores how advanced nuclear magnetic resonance (NMR) spectroscopy can sharpen head-to-head comparisons between Humira (adalimumab) and its biosimilars—particularly when products are challenged under real-world...
A new analytical study...
09/22/2025
First Report Managed Care
News
$3.2 Million Saved Through Biosimilar Substitution in Rheumatology Clinics
09/19/2025
Juliet Gallagher
A study published in the Journal of Clinical Rheumatology found that a recent initiative at a large academic medical center significantly increased biosimilar uptake and generated substantial cost savings through targeted interventions.
A study published in the Journal of Clinical Rheumatology found that a recent initiative at a large academic medical center significantly increased biosimilar uptake and generated substantial cost savings through targeted interventions.
A study published in the Journal...
09/19/2025
First Report Managed Care
News
Pharmacists Lead, Physicians Lag? Provider Perspectives on Biosimilars and Interchangeability
09/18/2025
Juliet Gallagher
A new cross-sectional survey of 249 US outpatient clinicians—150 physicians and 99 pharmacists who treat immunologic conditions—offers a timely snapshot of how front-line decision-makers view biosimilars and the US Food and Drug...
A new cross-sectional survey of 249 US outpatient clinicians—150 physicians and 99 pharmacists who treat immunologic conditions—offers a timely snapshot of how front-line decision-makers view biosimilars and the US Food and Drug...
A new cross-sectional survey of...
09/18/2025
First Report Managed Care
News
Payer-Driven Biosimilar Preferences Create Financial and Operational Strain for Health Systems
09/17/2025
Juliet Gallagher
The expansion of US Food and Drug Administration (FDA)-approved biosimilars has been heralded as a major advancement for lowering healthcare costs in the US, with the potential to reduce both system-wide expenditures and patient out-of-pocket...
The expansion of US Food and Drug Administration (FDA)-approved biosimilars has been heralded as a major advancement for lowering healthcare costs in the US, with the potential to reduce both system-wide expenditures and patient out-of-pocket...
The expansion of US Food and...
09/17/2025
First Report Managed Care
News
Biologics and Biosimilars Reshape Care With Targeted Therapies and Cost Savings
09/16/2025
Lisa Kuhns, PhD, MD
Both biologics and biosimilars are transforming patient care by delivering more targeted therapies and expanding access through cost savings, according to Andrew Darkow, PharmD, MBA, BCPS, during his presentation at the American Association...
Both biologics and biosimilars are transforming patient care by delivering more targeted therapies and expanding access through cost savings, according to Andrew Darkow, PharmD, MBA, BCPS, during his presentation at the American Association...
Both biologics and biosimilars...
09/16/2025
First Report Managed Care
News
FDA Issues Final Guidance on Biosimilar Prior Approval Supplements
09/10/2025
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug...
09/10/2025
First Report Managed Care
News
AAM White Paper Spotlights Legislative Path to Breaking Biosimilar Patent Barriers
08/18/2025
Grace Taylor, MS, MA
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the...
08/18/2025
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Videos Podcasts
Issue Content
Managed Care Q&A

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use